SMARCA4 and non-small cell lung carcinoma: Secondly, NSCLC patients with SMARCA4/KRAS co-mutations tended to have significantly worse overall survival than SMARCA4 WT/KRAS-mutated patients, regardless of treatment type, within each treatment analysis.